Jiangsu Hengrui Pharmaceuticals Co., Ltd. bought KLRA
April 20, 2026 · Form 4 insider transaction
Jiangsu Hengrui Pharmaceuticals Co., Ltd. bought 9,477,719 shares of Kailera Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
9,477,719
Price
N/A
Total value
N/A
Role—
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateApril 20, 2026
Filing dateApril 22, 2026
Shares owned after9,477,719
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.